相似文献
1
Establishing the Optimal Ceftriaxone MIC for Predicting ESBL Production in Bloodstream Infections.确定预测血流感染中产超广谱β-内酰胺酶（ESBL）的头孢曲松最低抑菌浓度（MIC）最佳值
Open Forum Infect Dis. 2025 Aug 14;12(9):ofaf490. doi: 10.1093/ofid/ofaf490. eCollection 2025 Sep.
2
Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.美国中大西洋地区耐头孢曲松肠杆菌血流感染中β-内酰胺酶的分子流行病学
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0125824. doi: 10.1128/aac.01258-24. Epub 2025 Jan 27.
3
Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.目前的头孢曲松剂量推荐方案适用于大多数危重症儿童：一项群体药代动力学建模和模拟研究的结果。
Clin Pharmacokinet. 2021 Oct;60(10):1361-1372. doi: 10.1007/s40262-021-01035-9. Epub 2021 May 26.
4
Analysis of Neisseria gonorrhoeae susceptibility trends (MIC creep) from North India: A 15-years' experience!印度北部淋病奈瑟菌药敏趋势（MIC 漂移）分析：15 年经验！
Indian J Dermatol Venereol Leprol. 2025 Jul-Aug;91(4):432-439. doi: 10.25259/IJDVL_1096_2024.
5
Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?碳青霉烯类治疗是否有必要用于治疗非 CTX-M 型超广谱β-内酰胺酶产生肠杆菌血流感染？
Clin Infect Dis. 2024 May 15;78(5):1103-1110. doi: 10.1093/cid/ciad703.
6
Oral and parenteral treatment with a third-generation cephalosporin promotes the proliferation of diverse ESBL-producing in the chicken intestinal tract.使用第三代头孢菌素进行口服和肠胃外治疗会促进鸡肠道中多种产超广谱β-内酰胺酶细菌的增殖。
mSphere. 2025 Jun 27:e0022725. doi: 10.1128/msphere.00227-25.
7
Unraveling Ceftriaxone Dosing: Free Drug Prediction, Threshold Optimization, and Model Validation.解读头孢曲松的给药剂量：游离药物预测、阈值优化及模型验证
AAPS J. 2025 Feb 26;27(2):50. doi: 10.1208/s12248-025-01041-w.
8
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in clinical isolates from the United States according to CLSI guidelines (2019-2021).根据美国临床和实验室标准协会（CLSI）指南（2019 - 2021年）重新评估青霉素和头孢曲松的最低抑菌浓度（MIC）结果，以预测美国临床分离株对口服头孢菌素头孢泊肟的敏感性。
J Clin Microbiol. 2025 Jun 24:e0002725. doi: 10.1128/jcm.00027-25.
9
Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus.抗生素组合对鹑鸡肠球菌和格氏肠球菌临床分离株的杀菌活性。
J Antimicrob Chemother. 2025 Jun 3;80(6):1519-1525. doi: 10.1093/jac/dkaf095.
10
Dissemination of extended-spectrum beta-lactamase-producing in poultry in Zimbabwe.津巴布韦家禽中产超广谱β-内酰胺酶细菌的传播情况。
Microb Genom. 2025 Jul;11(7). doi: 10.1099/mgen.0.001454.
本文引用的文献
1
Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.美国中大西洋地区耐头孢曲松肠杆菌血流感染中β-内酰胺酶的分子流行病学
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0125824. doi: 10.1128/aac.01258-24. Epub 2025 Jan 27.
2
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.美国传染病学会2024年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2024 Aug 7. doi: 10.1093/cid/ciae403.
3
Trends of β-Lactamase Occurrence Among and in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by β-Lactamase Type.美国医院5年期间内β-内酰胺酶产生情况的趋势以及抗菌药物对按β-内酰胺酶类型分层的分离株的活性。
Open Forum Infect Dis. 2023 Jan 27;10(2):ofad038. doi: 10.1093/ofid/ofad038. eCollection 2023 Feb.
4
Interpreting area under the receiver operating characteristic curve.解读受试者工作特征曲线下的面积
Lancet Digit Health. 2022 Dec;4(12):e853-e855. doi: 10.1016/S2589-7500(22)00188-1. Epub 2022 Oct 18.
5
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.超广谱β-内酰胺酶：其特性、流行病学及检测的最新进展
JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092. doi: 10.1093/jacamr/dlab092. eCollection 2021 Sep.
6
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.美罗培南或哌拉西林/他唑巴坦治疗患者的最低抑菌浓度、β-内酰胺酶基因与死亡率的关系：MERINO 研究。
Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850. doi: 10.1093/cid/ciaa1479.
7
Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.理解和应对 CLSI 折点修订：临床实验室的入门指南。
J Clin Microbiol. 2019 May 24;57(6). doi: 10.1128/JCM.00203-19. Print 2019 Jun.
8
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.哌拉西林-他唑巴坦与美罗培南对产 ESBLs 的大肠埃希菌或肺炎克雷伯菌血流感染且对头孢曲松耐药患者 30 天死亡率的影响：一项随机临床试验。
JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
9
Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae.肠杆菌科中抗生素使用与碳青霉烯类耐药性的相关性。
Antimicrob Agents Chemother. 2013 Oct;57(10):5131-3. doi: 10.1128/AAC.00607-13. Epub 2013 Jul 8.
10
Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.修订临床和实验室标准化研究所（CLSI）肠杆菌科和铜绿假单胞菌的临床和实验室标准解释标准（折点）的背景和原理：I. 头孢菌素和氨曲南。
Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18.
Zotero 插件